Sara Boveri

Dr. Sara Boveri

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2010 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
LMLucas Minig
Lucas Minig
DFD. Franchi
D. Franchi
SBSara Boveri
Sara Boveri
CCC. Casadio
C. Casadio
LBL. Bocciolone
L. Bocciolone
MSM. Sideri
M. Sideri
Background: To test the efficacy of levonorgestrel-release intrauterine device (LNG-IUD) plus gonadotropin-releasing hormone (GnRH) for treating women aged <40 years with atypical endometrial hyperplasia (AEH) or presumed International Federation of Gynecology and Obstetrics stage IA limited to the endometrium, well differentiated (G1), endometrioid endometrial cancer (EC), who wish to preserve their fertility. Patients and methods: A prospective observational study was conducted. Treatment consisted on the insertion of an LNG-IUD for 1 year plus GnRH analogue for 6 months. Results: From January 1996 to June 2009, 20 and 14 patients with AEH and EC, respectively, were studied. Complete response rate was 95% in patients with AEH and 57.1% in women with EC-G1. A progression of the disease was observed in one (5%) and in four patients (28%) with AEH and EC, respectively. Four of 20 patients with AEH and 2 of 14 with EC-G1 experienced recurrences. The average relapse time was 36 months (range: 16–62 months). All of them were alive without evidence of disease at the last follow-up, mean: 29 months (range: 4–102 months). Nine women achieved 11 spontaneous pregnancies. Conclusions: The combined treatment showed effectiveness in a substantial proportion of patients with AEH and EC. Close follow-up during and after treatment is crucial.

29 January 2015 in British Journal of Cancer
Verified
Journal Article
Open access
TGthe HPV Self-sampling Italian Working Group
the HPV Self-sampling Italian Working Group
PRPaolo Giorgi Rossi
Paolo Giorgi Rossi
CFC Fortunato
C Fortunato
PBP Barbarino
P Barbarino
SBSara Boveri
Sara Boveri
EMMA ALTOBELLIEMMA ALTOBELLI
EMMA ALTOBELLI
We performed a multicentre randomised controlled trial to evaluate the effect on participation in organised screening programmes of a self-sampling device mailed home or picked up at a pharmacy compared with the standard recall letter. Women aged 30-64 non-responding to screening invitation were eligible. Response rate to first invitation ranged from 30% to 60% between centres. The control was the standard reminder letter to undergo the test used by the programme (Pap test in three centres and HPV DNA test in three other centres). Home mailing of the self-sampler was preceded by a letter with a leaflet about HPV. The analysis was intention-to-treat. In all, 14 041 women were randomised and recruited: 5012 in the control arm, 4516 to receive the self-sampler at home, and 4513 to pick up the self-sampler at a pharmacy. Participation was 11.9% in the control, 21.6% (relative participation: 1.75; 95% CI 1.60-1.93) in home, and 12.0% (relative participation: 0.96; 95% CI 0.86-1.07) in the pharmacy arms, respectively. The heterogeneity between centres was high (excess heterogeneity of that expected due to chance, i.e., I(2), 94.9% and 94.1% for home and pharmacy arm, respectively). The estimated impact on the overall coverage was +4.3% for home mail self-sampling compared with +2.2% for standard reminder. Home mailing of self-sampler proved to be an effective way to increase participation in screening programmes, even in those with HPV as primary testing. Picking up at pharmacies showed effects varying from centre to centre.

1 April 2016 in Journal of Lower Genital Tract Disease
Verified
Journal Article
Closed access
LMLeonardo Micheletti
Leonardo Micheletti
MPMARIO PRETI
MARIO PRETI
GRGianluigi Radici
Gianluigi Radici
SBSara Boveri
Sara Boveri
OPOrazio Di Pumpo
Orazio Di Pumpo
CBChiara Benedetto
Chiara Benedetto
The aim of the study was to estimate the neoplastic potential of vulvar lichen sclerosus (VLS). This was a retrospective study of 976 women with VLS. We recorded age at diagnosis of VLS, length of follow-up, and type of neoplasia, categorized as the following: (1) vulvar intraepithelial neoplasia (VIN), further subdivided in differentiated VIN (dVIN) and high-grade squamous intraepithelial lesion; (2) superficially invasive squamous cell carcinoma; and (3) frankly invasive squamous cell carcinoma. Neoplasia incidence risk, neoplasia incidence rate, and cumulative probability of progression to neoplasia according to the Kaplan-Meier method were estimated. Log-rank test was used to compare the progression-free survival curves by age at diagnosis of VLS. The mean age at diagnosis of VLS was 60 (median = 60; range = 8-91) years. The mean length of follow-up was 52 (median = 21; range = 1-331) months. The following 34 patients developed a neoplasia: 8 VIN (4 dVIN, 4 high-grade squamous intraepithelial lesions), 6 keratinizing superficially invasive squamous cell carcinoma (5 with adjacent dVIN), and 20 keratinizing invasive squamous cell carcinoma (1 with adjacent dVIN). The neoplasia incidence risk was 3.5%. The neoplasia incidence rate was 8.1 per 1,000 person-years. The cumulative probability of progression to neoplasia increased from 1.2% at 24 months to 36.8% at 300 months. The median progression-free survival was significantly shorter in older women (≥70 years) when compared with that in younger women (p = .003). Vulvar lichen sclerosus has a nonnegligible risk of neoplastic transformation and requires a careful and lifelong follow-up in all patients, particularly in elderly women. Early clinical and histological detection of preinvasive lesions is essential to reduce the risk of vulvar cancer.

1 December 2011 in Gynecologic Oncology
Verified
Journal Article
Closed access
AMAndrea Maneo
Andrea Maneo
MSMario Sideri
Mario Sideri
GSGiovanni Scambia
Giovanni Scambia
SBSara Boveri
Sara Boveri
TDTiziana Dell'Anna
Tiziana Dell'Anna
FLFabio Landoni
Fabio Landoni

1 July 2016 in Gynecologic Oncology
Verified
Journal Article
Closed access
MSMichela Salvatici
Michela Salvatici
MAMaria T. Achilarre
Maria T. Achilarre
MSMaria T. Sandri
Maria T. Sandri
SBSara Boveri
Sara Boveri
ZVZanagnolo Vanna
Zanagnolo Vanna
FLFabio Landoni
Fabio Landoni

1 February 2013 in Gynecologic Oncology
Verified
Journal Article
Closed access
MSM.T. Sandri
M.T. Sandri
FBF. Bottari
F. Bottari
DFD. Franchi
D. Franchi
SBSara Boveri
Sara Boveri
MCM. Candiani
M. Candiani
MSM. Sideri
M. Sideri